bilaterals.org logo
bilaterals.org logo

intellectual property


RCEP talks: Farmers, civil society bodies warn against obligations on patenting seeds, plant varieties
Farmer and CSOs stressing that India should not agree to obligations with respect to IP on seed and planting materials at the RCEP negotiations as it hurt the livelihood of poor farmers.
Philippine civil society letter on RCEP & plant variety protection
The undersigned signatories are writing to strongly stress that the Regional Comprehensive Economic Partnership negotiations must not place any obligation on the Philippines or any other developing country to join or implement UPOV systems
Malaysian civil society & farmer groups’ memorandum on RCEP & plant variety protection
RCEP negotiations must not include obligation to join or implement UPOV systems and in anyway undermine farmers’ rights
Sign-on letter from India against IPR on seed
A mega free trade agreement, like RCEP that undermines farmers’ seed freedoms in a mega diverse country, with seed diversity and farmers’ knowledge is unacceptable, say over 50 groups and citizens
How drug prices could derail new trade pact to replace NAFTA
Democrats in Congress contend that the new pact would force Americans to pay more for prescription drugs, and their argument has dimmed the outlook for one of Trump’s signature causes.
Provision that could raise drug costs emerges as key obstacle to NAFTA approval
Some Democrats in the US, like Canada’s generic drug industry, warn that the new biologics rule would keep drug prices high by requiring citizens to wait longer before they can get their hands on lower-cost similar drugs known as biosimilars.
More than 70 US health, consumer and other groups demand elimination of NAFTA 2.0 terms that would lock in high US medicine prices
In a letter to Congress, the groups demand that the pact’s giveaways to Big Pharma that would keep medicines unaffordable be removed before the pact is sent to Congress.
We can’t afford to let the new NAFTA drive up drug prices
NAFTA 2.0 would effectively tie the US Congress’ hands in the struggle against rising drug prices.
The IP implications of the USMCA: Who needs to do what
The USMCA most closely reflects US IP laws, subjecting the US to almost no revisions of its current domestic intellectual property laws.
Free trade agreement with Indonesia to be signed in Jakarta on 16 December
Indonesia - EFTA trade deal will be signed, 98 per cent of Swiss exports to Indonesia will be exempt from customs duties over the coming years.
Comments on negotiating objectives for a US-Japan trade agreement
US drug manufacturers want Japan to provide 12 years of data protection for biologic medicine in upcoming trade talks. That would be four more years than Japan currently provides.
Japan to extend copyright period on works including novels and paintings to 70 years on Dec. 30
The copyright period on works such as novels and paintings in Japan is set to be extended to 70 years after the authors’ deaths, from the current 50 years, as part of legislation to approve the TPP.
NAFTA 2.0: US-Mexico-Canada Agreement. Chapter 20: pharmaceutical related patent provisions
The Intellectual Property Chapter of the revised NAFTA, rebranded by the Trump Administration USMCA, includes provisions that threaten to undermine critical efforts to­wards affordable health care and medicine.
Indonesia and RCEP: Beware the public health risks
Proposals from Japan and South Korea would require patent law changes in several RCEP countries, including Indonesia.
Switzerland should stop pushing for TRIPS-plus measures in trade agreement with Indonesia
Swiss and Norwegians civil society groups addressed their serious concerns over TRIPS-plus provisions being included in the trade agreement under negotiation between the European Free Trade Association (EFTA) and Indonesia.
RCEP and affordable medicines: Civil society reaches out to Minister of Commerce Suresh Prabhu
Civil society organisations, patient groups and health activists have been concerned about intellectual property provisions being discussed in RCEP which undermine access to medicines and affordable treatment for patients
Indonesia-EFTA CEPA TRIPS-plus, threat for access to medicines and the right to health of millions of people in Indonesia
In many countries, the implementation of the TRIPS-plus measures has significantly increased the cost of medicines.
Drugs costs impact health
Canada’s negotiators extended data protection on biologics without knowing impact on prices.
UPOV 91 and trade agreements: Compromising farmers’ right to save and sell seeds
Increased effort to include references to UPOV 91 in EU trade agreements impose intellectual property rights on seeds, which can restrict the farmers’ right to save and re-use seeds and undermine local seed systems
Trade and patent changes could increase healthcare costs by $100bn, CPHI annual report warns
Patients may need to wait an extra five or 10 years to access generic medicines, which could raise healthcare costs by as $100 billion over the next five years, according to the latest CPhI annual report